All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Virtual Vision Health Reaches 2.5 Million Exams and 1 Million Patients; UCLA Study Validates VR Eye Testing

7d ago· 4 min readen

Summary

Virtual Vision Health, a VR-based ophthalmic diagnostics company, announces it has surpassed 2.5 million exams and 1 million patients served globally since its inception less than four years ago. The company now supports over 1,800 eye care providers. This milestone follows new UCLA research presented at ARVO 2026 showing strong agreement between the company's VR-based visual field testing and the traditional Humphrey Field Analyzer standard of care, with patients reporting a more favorable testing experience. The company's VR portfolio includes visual field testing, visual acuity, contrast sensitivity, and ocular motility testing.

Source

bskyVirtual Vision Health Reaches 2.5 Million Exams and 1 Million Patients; UCLA Study Validates VR Eye Testingmorningstar.com

Key quotes

· 3 pulled
We believe virtual reality will play an increasingly important role in educating, diagnosing, and engaging patients throughout their healthcare journey.
These milestones are not simply a reflection of our growth, they are evidence that providers around the world are embracing a new model for delivering vision care.
Virtual Vision Health aims to provide eye care professionals with a better way to diagnose and manage ocular conditions.
Snippet from the RSS feed
Virtual Vision Health Surpasses 2.5 Million Exams and 1 Million Patients Worldwide Virtual Vision Health Surpasses 2.5 Million Exams and 1 Million Patients Worldwide P

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.